{"id":145,"date":"2023-07-07T14:34:23","date_gmt":"2023-07-07T14:34:23","guid":{"rendered":"https:\/\/epsilogen.com\/?post_type=team&#038;p=145"},"modified":"2024-04-10T13:32:18","modified_gmt":"2024-04-10T13:32:18","slug":"nick-robbins-cherry","status":"publish","type":"team","link":"https:\/\/epsilogen.com\/team\/nick-robbins-cherry\/","title":{"rendered":"Nick Robbins-Cherry"},"content":{"rendered":"<p>Nick brings over 30 years of experience in fundraising, public markets and private equity, gained through financial and commercial roles in international pharmaceuticals and technology businesses. Most recently, Nick was CFO of Ixaka Ltd, a private cell and gene therapy company. Prior to this, Nick was CFO at Midatech Pharma PLC, a listed pharmaceutical business with operations in the UK and Spain. He successfully steered Midatech through its IPO on AIM, a dual listing on NASDAQ and subsequent fundraises. Nick is a Chartered Accountant and holds an MBA and a BSc in Pharmacology from Bath University.<\/p>\n","protected":false},"featured_media":2141,"template":"","acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Nick Robbins-Cherry - Epsilogen<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/epsilogen.com\/team\/nick-robbins-cherry\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nick Robbins-Cherry - Epsilogen\" \/>\n<meta property=\"og:description\" content=\"Nick brings over 30 years of experience in fundraising, public markets and private equity, gained through financial and commercial roles in international pharmaceuticals and technology businesses. Most recently, Nick was CFO of Ixaka Ltd, a private cell and gene therapy company. Prior to this, Nick was CFO at Midatech Pharma PLC, a listed pharmaceutical business [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/epsilogen.com\/team\/nick-robbins-cherry\/\" \/>\n<meta property=\"og:site_name\" content=\"Epsilogen\" \/>\n<meta property=\"article:modified_time\" content=\"2024-04-10T13:32:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/epsilogen.com\/wp-content\/uploads\/2023\/07\/Nick.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t<meta property=\"og:image:height\" content=\"667\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/epsilogen.com\/team\/nick-robbins-cherry\/\",\"url\":\"https:\/\/epsilogen.com\/team\/nick-robbins-cherry\/\",\"name\":\"Nick Robbins-Cherry - Epsilogen\",\"isPartOf\":{\"@id\":\"https:\/\/epsilogen.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/epsilogen.com\/team\/nick-robbins-cherry\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/epsilogen.com\/team\/nick-robbins-cherry\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/epsilogen.com\/wp-content\/uploads\/2023\/07\/Nick.png\",\"datePublished\":\"2023-07-07T14:34:23+00:00\",\"dateModified\":\"2024-04-10T13:32:18+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/epsilogen.com\/team\/nick-robbins-cherry\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/epsilogen.com\/team\/nick-robbins-cherry\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/epsilogen.com\/team\/nick-robbins-cherry\/#primaryimage\",\"url\":\"https:\/\/epsilogen.com\/wp-content\/uploads\/2023\/07\/Nick.png\",\"contentUrl\":\"https:\/\/epsilogen.com\/wp-content\/uploads\/2023\/07\/Nick.png\",\"width\":1000,\"height\":667},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/epsilogen.com\/team\/nick-robbins-cherry\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/epsilogen.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nick Robbins-Cherry\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/epsilogen.com\/#website\",\"url\":\"https:\/\/epsilogen.com\/\",\"name\":\"Epsilogen\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/epsilogen.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/epsilogen.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/epsilogen.com\/#organization\",\"name\":\"Epsilogen\",\"url\":\"https:\/\/epsilogen.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/epsilogen.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/epsilogen.com\/wp-content\/uploads\/2023\/07\/logo.svg\",\"contentUrl\":\"https:\/\/epsilogen.com\/wp-content\/uploads\/2023\/07\/logo.svg\",\"width\":267,\"height\":64,\"caption\":\"Epsilogen\"},\"image\":{\"@id\":\"https:\/\/epsilogen.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nick Robbins-Cherry - Epsilogen","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/epsilogen.com\/team\/nick-robbins-cherry\/","og_locale":"en_US","og_type":"article","og_title":"Nick Robbins-Cherry - Epsilogen","og_description":"Nick brings over 30 years of experience in fundraising, public markets and private equity, gained through financial and commercial roles in international pharmaceuticals and technology businesses. Most recently, Nick was CFO of Ixaka Ltd, a private cell and gene therapy company. Prior to this, Nick was CFO at Midatech Pharma PLC, a listed pharmaceutical business [&hellip;]","og_url":"https:\/\/epsilogen.com\/team\/nick-robbins-cherry\/","og_site_name":"Epsilogen","article_modified_time":"2024-04-10T13:32:18+00:00","og_image":[{"width":1000,"height":667,"url":"https:\/\/epsilogen.com\/wp-content\/uploads\/2023\/07\/Nick.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/epsilogen.com\/team\/nick-robbins-cherry\/","url":"https:\/\/epsilogen.com\/team\/nick-robbins-cherry\/","name":"Nick Robbins-Cherry - Epsilogen","isPartOf":{"@id":"https:\/\/epsilogen.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/epsilogen.com\/team\/nick-robbins-cherry\/#primaryimage"},"image":{"@id":"https:\/\/epsilogen.com\/team\/nick-robbins-cherry\/#primaryimage"},"thumbnailUrl":"https:\/\/epsilogen.com\/wp-content\/uploads\/2023\/07\/Nick.png","datePublished":"2023-07-07T14:34:23+00:00","dateModified":"2024-04-10T13:32:18+00:00","breadcrumb":{"@id":"https:\/\/epsilogen.com\/team\/nick-robbins-cherry\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/epsilogen.com\/team\/nick-robbins-cherry\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/epsilogen.com\/team\/nick-robbins-cherry\/#primaryimage","url":"https:\/\/epsilogen.com\/wp-content\/uploads\/2023\/07\/Nick.png","contentUrl":"https:\/\/epsilogen.com\/wp-content\/uploads\/2023\/07\/Nick.png","width":1000,"height":667},{"@type":"BreadcrumbList","@id":"https:\/\/epsilogen.com\/team\/nick-robbins-cherry\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/epsilogen.com\/"},{"@type":"ListItem","position":2,"name":"Nick Robbins-Cherry"}]},{"@type":"WebSite","@id":"https:\/\/epsilogen.com\/#website","url":"https:\/\/epsilogen.com\/","name":"Epsilogen","description":"","publisher":{"@id":"https:\/\/epsilogen.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/epsilogen.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/epsilogen.com\/#organization","name":"Epsilogen","url":"https:\/\/epsilogen.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/epsilogen.com\/#\/schema\/logo\/image\/","url":"https:\/\/epsilogen.com\/wp-content\/uploads\/2023\/07\/logo.svg","contentUrl":"https:\/\/epsilogen.com\/wp-content\/uploads\/2023\/07\/logo.svg","width":267,"height":64,"caption":"Epsilogen"},"image":{"@id":"https:\/\/epsilogen.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/epsilogen.com\/wp-json\/wp\/v2\/team\/145"}],"collection":[{"href":"https:\/\/epsilogen.com\/wp-json\/wp\/v2\/team"}],"about":[{"href":"https:\/\/epsilogen.com\/wp-json\/wp\/v2\/types\/team"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/epsilogen.com\/wp-json\/wp\/v2\/media\/2141"}],"wp:attachment":[{"href":"https:\/\/epsilogen.com\/wp-json\/wp\/v2\/media?parent=145"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}